To include your compound in the COVID-19 Resource Center, submit it here.

Avilex: One-two pain punch

Avilex's dimeric inhibitor shows greater potency for pain target PSD95

Avilex Pharma ApS may have found a way to block activation of the NMDA receptor pathway to treat chronic pain and ischemic stroke. Rather than directly hitting the receptor itself, the approach targets a downstream player in the pathway and thus could avoid many of the side effects of NMDA receptor antagonists.

The NMDA receptor is expressed on the surface of many CNS cell types and is known to mediate production of excess nitric oxide (NO), which leads

Read the full 777 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE